Search results
14 lis 2023 · Salmonella Vaccine Study in Oxford is a first-in-human study of a novel vaccine against invasive non-typhoidal Salmonellosis (iNTS), a neglected disease largely affecting low- and middle-income countries.
14 lis 2023 · While NTS livestock vaccines are in wide use, no licensed vaccines exist for use in humans. Here, a first-in-human study of a novel vaccine (iNTS-GMMA) containing S. Typhimurium and S. Enteritidis Generalised Modules for Membrane Antigens (GMMA) outer membrane vesicles is presented.
14 lis 2023 · Method and analysis: The Salmonella Vaccine Study in Oxford is a randomised placebo-controlled participant-observer blind phase I study of the iNTS-GMMA vaccine.
14 cze 2017 · This review compiles the current knowledge acquired from past and present studies that have helped to define key parameters instrumental in the design of an efficient anti-Salmonella vaccine. Mechanisms of Salmonella -host interaction resulting in bacterial uptake, as well as the innate and adaptive anti- Salmonella protective immunity, are ...
There are currently three vaccines licensed for use in humans, all targeting typhoidal Salmonella: the live attenuated oral vaccine S. Typhi Ty21a, Vi capsule polysaccharide vaccine, and Vi polysaccharide conjugated with tetanus toxoid (11 – 14). Despite extensive efforts, no human vaccine targeting NTS has yet been licensed.
In this review we focus on (1) recent advances in live attenuated Salmonella vaccine development, (2) improvements in expression of foreign antigens in carrier vaccines and (3) adaptation of attenuated strains as sources of purified antigens and vesicles that can be used for subunit and conjugate vaccines or together with attenuated vaccine ...
This study is a first-in-human clinical trial involving 30-42 healthy adult participants who will be randomly allocated to receive either iNTS-GMMA or a placebo. The main objective of this trial is to evaluate the safety of the iNTS-GMMA vaccine in healthy adults in the UK.
